N/A N=77 Intermittent Fasting and a No-Sugar Diet for Long COVID Symptoms
Long Covid19 · Long COVID
Primary: Change in LC-Score, Per Treatment — -10.2; -2.8 Scores on a Scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=500 "Safety in Dementia": An Online Caregiver Intervention
Caregivers · Decision Making · Alzheimer Disease
Primary: Preparation for Decision Making — 64.8; 69.8; 69.7; 73.7 score on a scale
N/A N=16 Improving Physical Activity With Cognitive Impairment
Mild Cognitive Impairment · Caregiver Burnout
Primary: TPAB Intervention Participant Retention — 5; 5; 3; 3 Participants
N/A N=20 Cognitive Priming for Stroke Tele-rehabilitation
Stroke
Primary: Change From Baseline in Global Cognition, as Measured by the Montreal Cognitive Assessment (MoCA) — 1.74 total score — p=.012
N/A N=143 Defibrillation Testing During Implantable Cardioverter Defibrillator (ICD) Replacement
Implantable Cardioverter-Defibrillators
Primary: Rate of Defibrillator Electrical Integrity Dysfunction During Generator Replacement. — 1 Participants
Phase 2 N=140 Polypill in Acute Coronary Syndrome
Acute Coronary Syndrome · Lipid Disorder · Coronary Artery Disease
Primary: Low Density Lipoprotein - Cholesterol — -6.74; 0.53 mg/dL — p=0.27
N/A N=86 Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.
Prostate Cancer · Metastasis · Toxicity Due to Radiotherapy
Primary: Median Progression-Free Survival (PFS) — 6.0 months — p=0.001
N/A N=131 Subchondroplasty® Knee RCT
Bone Marrow Edema · Knee Pain Chronic · Knee Osteoarthritis
Primary: Composite Clinical Success — 68; 38; 16; 4 Participants — p=>0.01
Phase 3 N=1,164 Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
Contraception
Primary: Contraceptive Efficacy of Relugolix Combination Therapy as Assessed by the At-Risk Pearl Index (PI) — 1.27 Pregnancies per 100 woman-years
Phase 2 N=18 HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
HPV-Related Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) at 2 Years — 75.5 percentage of patients
N/A N=70 Hand Reflexology for Fatigue and Anxiety in Hemodialysis Patients
End Stage Kidney Disease (ESRD) · Hemodialysis · Anxiety
Primary: Change in Fatigue Levels as Measured by the Arabic FACIT-Fatigue Scale (FACIT-F) — 24.4; 21.7; 29.5; 21.2 Points on FACIT-Fatigue Scale
Phase 1 N=6 Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
B-precursor Acute Lymphoblastic Leukemia
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-related TEAEs — 5; 1; 1; 0 Participants
Phase 2 N=100 A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study
Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck
Primary: Progression Free Survival (PFS) — 49.7; 35.3 percentage of participants — p=0.067
Phase 4 N=240 Intermittent Bolus vs Continuous Infusion Via ESP Catheters RCT
Post Operative Pain
Primary: Opioid Consumption POD 1 — 86.6; 90.5 MME
N/A N=100 Feasibility of Obtaining Pulse Oximetry Readings From the Oropharynx
Surgery · Arterial Catheterization, Peripheral
Primary: Oropharyngeal vs Extremity Saturation — 98; 98; 95; 99 percent of oxygen saturation